{"id":"https://openalex.org/W3132959103","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-18","title":"Abstract PS11-18: Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): Results of phase I expansion cohorts","display_name":"Abstract PS11-18: Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): Results of phase I expansion cohorts","publication_year":2021,"publication_date":"2021-02-15","ids":{"openalex":"https://openalex.org/W3132959103","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-18","mag":"3132959103"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs20-ps11-18","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-18","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-18","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000462280","display_name":"Emma Jane Dean","orcid":"https://orcid.org/0000-0001-9956-257X","observed_orcids":["https://orcid.org/0000-0001-9956-257X"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Emma Dean","raw_affiliation_strings":["1AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080991347","display_name":"Matthew Krebs","orcid":"https://orcid.org/0000-0001-7540-3064","observed_orcids":["https://orcid.org/0000-0001-7540-3064"]},"institutions":[{"id":"https://openalex.org/I28407311","display_name":"University of Manchester","ror":"https://ror.org/027m9bs27","country_code":"GB","type":"education","lineage":["https://openalex.org/I28407311"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matthew G Krebs","raw_affiliation_strings":["2The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom","institution_ids":["https://openalex.org/I28407311","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069050806","display_name":"Seock\u2010Ah Im","orcid":"https://orcid.org/0000-0002-5396-6533","observed_orcids":["https://orcid.org/0000-0002-5396-6533"]},"institutions":[{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Seock-Ah Im","raw_affiliation_strings":["3Seoul National University Hospital, Seoul, Korea, Republic of"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Seoul National University Hospital, Seoul, Korea, Republic of","institution_ids":["https://openalex.org/I2802835388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071553983","display_name":"Mario Campone","orcid":"https://orcid.org/0000-0002-5196-5908","observed_orcids":["https://orcid.org/0000-0002-5196-5908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mario Campone","raw_affiliation_strings":["4Institut de Cancerologie de l'Ouest, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Institut de Cancerologie de l'Ouest, Nantes, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008444865","display_name":"Sophie C. Postel-Vinay","orcid":"https://orcid.org/0000-0001-5562-1857","observed_orcids":["https://orcid.org/0000-0001-5562-1857"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Sophie Postel-Vinay","raw_affiliation_strings":["5Institut Gustave Roussy, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Institut Gustave Roussy, Paris, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012989377","display_name":"Hendrik\u2010Tobias Arkenau","orcid":"https://orcid.org/0000-0002-2015-1549","observed_orcids":["https://orcid.org/0000-0002-2015-1549","https://orcid.org/0000-0003-0372-0540"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Tobias Arkenau","raw_affiliation_strings":["6Sarah Cannon Research UK, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Sarah Cannon Research UK, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064237640","display_name":"Juanita Suzanne Lopez","orcid":"https://orcid.org/0000-0001-8321-4212","observed_orcids":["https://orcid.org/0000-0001-8321-4212"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Juanita Lopez","raw_affiliation_strings":["7The Royal Marsden NHS Foundation Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7The Royal Marsden NHS Foundation Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062426672","display_name":"Wassim M. Abida","orcid":"https://orcid.org/0000-0002-9006-7043","observed_orcids":["https://orcid.org/0000-0002-9006-7043"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wassim Abida","raw_affiliation_strings":["8Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071360446","display_name":"Duncan Ian Jodrell","orcid":"https://orcid.org/0000-0001-9360-1670","observed_orcids":["https://orcid.org/0000-0001-9360-1670"]},"institutions":[{"id":"https://openalex.org/I241749","display_name":"University of Cambridge","ror":"https://ror.org/013meh722","country_code":"GB","type":"education","lineage":["https://openalex.org/I241749"]},{"id":"https://openalex.org/I2802466933","display_name":"Cambridge University Hospitals NHS Foundation Trust","ror":"https://ror.org/04v54gj93","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2802466933"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Duncan Jodrell","raw_affiliation_strings":["9Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I241749","https://openalex.org/I2802466933"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084847095","display_name":"Keun\u2010Wook Lee","orcid":"https://orcid.org/0000-0002-8491-703X","observed_orcids":["https://orcid.org/0000-0002-8491-703X"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I2803058125","display_name":"Seoul National University Bundang Hospital","ror":"https://ror.org/00cb3km46","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388","https://openalex.org/I2803058125"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Keun-Wook Lee","raw_affiliation_strings":["10Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of","institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2803058125"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024676627","display_name":"Sun Young Rha","orcid":"https://orcid.org/0000-0002-2512-4531","observed_orcids":["https://orcid.org/0000-0002-2512-4531"]},"institutions":[{"id":"https://openalex.org/I193775966","display_name":"Yonsei University","ror":"https://ror.org/01wjejq96","country_code":"KR","type":"education","lineage":["https://openalex.org/I193775966"]},{"id":"https://openalex.org/I4210160791","display_name":"Yonsei University Health System","ror":"https://ror.org/04sze3c15","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I193775966","https://openalex.org/I4210160791"]},{"id":"https://openalex.org/I4405258038","display_name":"Yonsei Cancer Hospital","ror":"https://ror.org/0005vby86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I193775966","https://openalex.org/I2799970807","https://openalex.org/I4210160791","https://openalex.org/I4405258038"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"SunYoung Rha","raw_affiliation_strings":["11Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of","institution_ids":["https://openalex.org/I193775966","https://openalex.org/I4210160791","https://openalex.org/I4405258038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055664434","display_name":"Irene M. Kang","orcid":"https://orcid.org/0000-0002-9472-3853","observed_orcids":["https://orcid.org/0000-0002-9472-3853"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Irene Kang","raw_affiliation_strings":["12University of Southern California, Los Angeles, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12University of Southern California, Los Angeles, CA;","institution_ids":["https://openalex.org/I1174212"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049781940","display_name":"Rebecca R. Roylance","orcid":"https://orcid.org/0000-0003-1453-6343","observed_orcids":["https://orcid.org/0000-0003-1453-6343"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rebecca Roylance","raw_affiliation_strings":["13University College London, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112615847","display_name":"Graeme Parr","orcid":"https://orcid.org/0009-0000-1843-4809","observed_orcids":["https://orcid.org/0009-0000-1843-4809"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Graeme Parr","raw_affiliation_strings":["1AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035341984","display_name":"Claire Smith","orcid":"https://orcid.org/0000-0002-3029-6207","observed_orcids":["https://orcid.org/0000-0002-3029-6207"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claire Smith","raw_affiliation_strings":["1AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041014338","display_name":"Andrew Goldwin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Andrew Goldwin","raw_affiliation_strings":["1AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025426775","display_name":"Elhan Sanai","orcid":"https://orcid.org/0009-0000-9615-7173","observed_orcids":["https://orcid.org/0009-0000-9615-7173"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Elhan Sanay","raw_affiliation_strings":["1AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031466705","display_name":"Natasha Lukashchuk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Natasha Lukashchuk","raw_affiliation_strings":["1AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055277039","display_name":"Alan Lau","orcid":"https://orcid.org/0000-0003-1055-9812","observed_orcids":["https://orcid.org/0000-0003-1055-9812"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alan Lau","raw_affiliation_strings":["1AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082781519","display_name":"Andrew J. Pierce","orcid":"https://orcid.org/0000-0001-9062-0307","observed_orcids":["https://orcid.org/0000-0001-9062-0307","https://orcid.org/0000-0003-0942-0370","https://orcid.org/0000-0002-0738-2756"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Andrew Pierce","raw_affiliation_strings":["1AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018568000","display_name":"Bienvenu Loemb\u00e9","orcid":"https://orcid.org/0009-0001-2557-8170","observed_orcids":["https://orcid.org/0009-0001-2557-8170"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Bienvenu Loembe","raw_affiliation_strings":["1AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":17,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"81","issue":"4_Supplement","first_page":"PS11","last_page":"18"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ceralasertib","display_name":"ceralasertib","score":0.9950000047683716},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.9890000224113464},{"id":"https://openalex.org/keywords/atr-inhibitors","display_name":"ATR inhibitors","score":0.8069999814033508},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9700000286102295},{"id":"https://openalex.org/keywords/advanced-breast-cancer","display_name":"advanced breast cancer","score":0.8199999928474426},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8669999837875366},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.8619999885559082},{"id":"https://openalex.org/keywords/germline-brca-mutation","display_name":"germline BRCA mutation","score":0.8629999756813049},{"id":"https://openalex.org/keywords/homologous-recombination-repair","display_name":"homologous recombination repair","score":0.8610000014305115},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.652999997138977},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.824999988079071},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8399999737739563},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7229999899864197},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.5680000185966492}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8525924682617188},{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.8403828144073486},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6489466428756714},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6479041576385498},{"id":"https://openalex.org/C2780194787","wikidata":"https://www.wikidata.org/wiki/Q4836333","display_name":"BRCA mutation","level":4,"score":0.6332202553749084},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6252691745758057},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6179789900779724},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.5678231120109558},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5250235199928284},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4238443374633789},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.4139372408390045},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.41199612617492676},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3254633843898773},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2553523778915405},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.09182322025299072},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1538-7445.sabcs20-ps11-18","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-18","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-18","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/a9c2751b-972b-48ee-9453-91c6635dc637","doi":null,"is_oa":false,"landing_page_url":"https://research.manchester.ac.uk/en/publications/a9c2751b-972b-48ee-9453-91c6635dc637","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Dean, E, Krebs, M, Im, S-A, Campone, M, Postel-Vinay, S, Arkenau, T, Lopez, J, Abida, W, Jodrell, D, Lee, K-W, Rha, S, Kang, I, Roylance, R, Parr, G, Smith, C, Goldwin, A, Sanay, E, Lukashchuk, N, Lau, A & Loembe, B 2021, 'Abstract PS11-18: Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC) : Results of phase I expansion cohorts'. https://doi.org/10.1158/1538-7445.SABCS20-PS11-18","raw_type":"info:eu-repo/semantics/conferenceObject"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7214962482","https://openalex.org/W7162559898","https://openalex.org/W3198165388","https://openalex.org/W4387157290","https://openalex.org/W4410812240","https://openalex.org/W3203516197","https://openalex.org/W4366983764","https://openalex.org/W4399380737","https://openalex.org/W7213916673","https://openalex.org/W4414221653"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Alterations":[2],"in":[3,36,123,133,239,273,403,421,425,434,495,502,509,567,572],"BRCA1/2":[4,208],"are":[5,463,505],"associated":[6],"with":[7,24,28,125,130,144,151,337,405,466,478,487,569,575],"~9%":[8],"of":[9,63,72,85,97,117,155,168,199,220,227,256,261,289,294,358,430,454,581,589],"all":[10,190,306,422],"BCs.":[11],"Ola":[12],"(a":[13],"poly":[14],"ADP-ribose":[15],"polymerase":[16],"inhibitor":[17],"[PARPi])":[18],"is":[19,78],"approved":[20],"for":[21,170,196,442],"treating":[22],"pts":[23,124,143,160,191,236,264,271,297,353,381,397,404,423,462,477],"HER2-negative":[25],"metastatic":[26,171],"BC":[27,148],"germline":[29,205],"BRCA":[30],"mutation":[31],"(gBRCAm),":[32],"demonstrating":[33],"an":[34],"improvement":[35],"progression-free":[37],"survival":[38],"(PFS).":[39],"Ceralasertib":[40,565],"(an":[41],"ataxia":[42],"telangiectasia":[43],"and":[44,53,142,173,218,321,361,394],"Rad3-related":[45],"protein":[46],"ATR":[47],"inhibitor)":[48],"targets":[49],"DNA":[50],"damage":[51],"repair":[52,136],"cell":[54],"cycle":[55],"regulation.":[56],"Preclinical":[57],"studies":[58],"show":[59],"synergistic":[60],"antitumor":[61],"effects":[62],"ola+cer":[64,98,122],"vs":[65],"ola":[66,100],"monotherapy":[67],"supporting":[68],"the":[69,92,115,216,221,240,274,343,376,426,431,435,590],"clinical":[70,483],"evaluation":[71],"this":[73,496,503],"combination.":[74],"Methods:":[75],"Study":[76],"4":[77],"a":[79,152,184,193,200,355,383,406,443,467,510],"modular":[80],"multicenter":[81,512],"Phase":[82,94,497,515],"I":[83,498,583],"study":[84,440,504],"cer":[86,106],"combinations":[87],"(NCT02264678).":[88],"Module":[89],"2":[90,95,260,516],"established":[91],"Recommended":[93],"Dose":[96],"as":[99],"300":[101],"mg":[102,108],"bid":[103],"daily":[104],"+":[105],"160":[107],"qd":[109],"D1-7":[110],"q":[111],"28d.":[112],"We":[113],"report":[114],"results":[116],"two":[118],"expansion":[119,584],"cohorts":[120,585],"testing":[121],"triple":[126],"negative":[127],"breast":[128,481,577],"cancer":[129,578],"no":[131,347],"alterations":[132],"homologous":[134],"recombination":[135],"(HRR)-related":[137],"genes":[138],"(HRR":[139],"wt":[140,242,345],"group),":[141,150],"advanced":[145,576],"HER2-":[146,479],"BRCAm":[147,186,275,377,409,427,436,480],"(BRCAm":[149],"data":[153,459],"cut-off":[154],"19th":[156],"June":[157,456],"2019.":[158],"Eligible":[159],"had":[161,266,299,364],"to":[162,214,451,472],"have":[163,179],"received":[164,267,300],"1-2":[165],"prior":[166,257,268,290,301,450],"lines":[167,259,292],"chemotherapy":[169,258,291],"disease,":[172],"were":[174,237,311,349,438],"PARPi":[175],"naive.":[176],"Patients":[177],"may":[178],"enrolled":[180,238,272,424],"directly":[181],"based":[182],"on":[183,439],"local":[185],"test":[187],"result,":[188],"but":[189],"submitted":[192],"tumor":[194],"specimen":[195],"central":[197],"confirmation":[198],"deleterious":[201],"(or":[202],"suspected":[203],"deleterious)":[204],"or":[206],"somatic":[207],"mutation.":[209],"The":[210,303,367,400,500],"primary":[211],"objective":[212,228],"was":[213,370,410,485],"investigate":[215],"safety":[217],"tolerability":[219],"combination;":[222],"secondary":[223],"objectives":[224],"included":[225,330],"assessment":[226],"response":[229,357,385,490],"rate":[230],"by":[231],"RECIST":[232],"1.1.":[233],"Results:":[234],"Twenty-five":[235],"HRR":[241,344],"group:":[243,276],"median":[244,254,277,287,368,401],"age":[245,278],"53":[246],"(31-75),":[247],"ECOG":[248,281],"PS":[249,282],"0/1":[250,283],"13":[251,362,379,432],"(52%)/12":[252],"(48%),":[253],"number":[255,288],"which":[262,295],"8":[263],"(32%)":[265,320],"platinum.":[269,302],"Thirty-seven":[270],"51":[279],"(24-69),":[280],"20":[284,319,323,471],"(54%)/17":[285],"(46%),":[286],"1":[293,387],"19":[296],"(51%)":[298],"most":[304],"frequent":[305],"causality":[307],"Adverse":[308],"Events":[309],"(AEs)":[310],"nausea":[312],"43":[313],"(69%),":[314],"anemia":[315,331],"36":[316],"(58%),":[317],"diarrhea":[318],"vomiting":[322],"(32%);":[324],"CTCAE":[325],"\u2265":[326],"Grade":[327],"3":[328],"AEs":[329],"15":[332],"(24%),":[333],"neutropenia":[334],"6":[335],"(10%)":[336],"few":[338],"patients":[339,573],"discontinuing":[340],"treatment.":[341],"In":[342,375,476],"group,":[346,378],"responses":[348],"observed,":[350],"12":[351],"(48%)":[352],"achieved":[354,382],"best":[356],"stable":[359,392],"disease":[360,365,393,398],"(52%)":[363],"progression.":[366,399],"PFS":[369,402],"3.1":[371],"months":[372,412,417],"(80%CI":[373,413,418],"2.0,3.9).":[374],"(35%)":[380],"confirmed":[384,408],"(including":[386],"complete":[388],"response),":[389],"17":[390],"(46%)":[391],"7":[395],"(19%)":[396],"centrally":[407],"11.5":[411],"5.8-14.8,":[414],"n=30),":[415],"7.7":[416],"5.8-11.4,":[419],"n=37)":[420],"group.":[428],"Eleven":[429],"responders":[433],"group":[437],"treatment":[441,448,468],"longer":[444],"duration":[445,469],"than":[446],"their":[447],"immediately":[449],"enrollment.":[452],"As":[453],"18th":[455],"20,":[457],"preliminary":[458],"shows":[460],"10":[461],"still":[464],"ongoing":[465],"ranging":[470],"35":[473],"months.":[474],"Conclusion:":[475],"cancer,":[482],"efficacy":[484],"observed":[486],"durable":[488],"radiological":[489],"despite":[491],"adverse":[492],"prognostic":[493],"features":[494],"population.":[499],"observations":[501],"currently":[506],"being":[507],"tested":[508],"global":[511],"open-label":[513],"randomised":[514],"study:":[517],"VIOLETTE":[518],"(NCT03330847).":[519],"Citation":[520],"Format:":[521],"Emma":[522],"Dean,":[523],"Matthew":[524],"G":[525],"Krebs,":[526],"Seock-Ah":[527],"Im,":[528],"Mario":[529],"Campone,":[530],"Sophie":[531],"Postel-Vinay,":[532],"Tobias":[533],"Arkenau,":[534],"Juanita":[535],"Lopez,":[536],"Wassim":[537],"Abida,":[538],"Duncan":[539],"Jodrell,":[540],"Keun-Wook":[541],"Lee,":[542],"SunYoung":[543],"Rha,":[544],"Irene":[545],"Kang,":[546],"Rebecca":[547],"Roylance,":[548],"Graeme":[549],"Parr,":[550],"Claire":[551],"Smith,":[552],"Andrew":[553,561],"Goldwin,":[554],"Elhan":[555],"Sanay,":[556],"Natasha":[557],"Lukashchuk,":[558],"Alan":[559],"Lau,":[560],"Pierce,":[562],"Bienvenu":[563],"Loembe.":[564],"(cer)":[566],"combination":[568],"olaparib":[570],"(ola)":[571],"(pts)":[574],"(BC):":[579],"Results":[580],"phase":[582],"[abstract].":[586],"In:":[587],"Proceedings":[588],"2020":[591,598],"San":[592,601],"Antonio":[593],"Breast":[594],"Cancer":[595,607],"Virtual":[596],"Symposium;":[597],"Dec":[599],"8-11;":[600],"Antonio,":[602],"TX.":[603],"Philadelphia":[604],"(PA):":[605],"AACR;":[606],"Res":[608],"2021;81(4":[609],"Suppl):Abstract":[610],"nr":[611],"PS11-18.":[612]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2021-03-01T00:00:00"}